Researchers genotyped advanced cancer patients treated with immunotherapies and found that homozygosity at HLA loci was linked to decreased survival.
Memorial Sloan Kettering Cancer Center also hopes its partnership with analytics vendor Cota will help it prepare for value-based reimbursement.
The authorization implements regulatory strategies the FDA advanced with industry stakeholders, though labs may still be more inclined to take the CLIA route, as long as it is available.
The agency said that its action on MSK IMPACT "advances a policy framework that paves the way for the efficient review and availability of other NGS-based cancer profiling tools."
Analytics vendor Cota will classify records from Memorial Sloan Kettering in hopes of improving cancer care and research.
Pathoquest will compare its iDtect blood test with standard testing methods to identify microbes causing infections in patients with febrile neutropenia.
Researchers will use the company's Colvera assay to track biomarkers in rectal cancer patients before, during, and after treatment.
In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.
Researchers found that ADAR works by stabilizing the FAK gene, which is one of a subset involved in cell migration pathways.
Stat News reports that IBM's Watson for Oncology isn't yet living up to its promise.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.